Base de dados : MEDLINE
Pesquisa : D02.033.100.624.698.711 [Categoria DeCS]
Referências encontradas : 31575 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3158 ir para página                         

  1 / 31575 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287888
[Au] Autor:Espahbodi M; Yan K; Chun RH; McCormick ME
[Ad] Endereço:Medical College of Wisconsin, Department of Otolaryngology & Communication Sciences, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. Electronic address: mespahbodi@gmail.com.
[Ti] Título:Management trends of infantile hemangioma: A national perspective.
[So] Source:Int J Pediatr Otorhinolaryngol;104:84-87, 2018 Jan.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The primary management of infantile hemangioma (IH) has changed since 2008, with the initiation of propranolol. The change that propranolol has affected on resource utilization is unknown. MATERIALS AND METHODS: The Kids' Inpatient Database (KID) in 2003, 2006, 2009, and 2012 was queried for ICD-9 codes for IH in children under age three. The number of patients undergoing the following procedures of interest: tracheostomy, tracheoscopy and laryngoscopy with biopsy, and excision of skin lesion were evaluated. Data was analyzed for demographics and details on the admission. Trends were identified. Weighted statistical analyses were performed with SAS 9.4. RESULTS: The number of qualified admissions significantly increased over the years (9271 in 2003-12029 in 2012, OR 1.042 per year increase, p < 0.001). The mean age at admission ranged from 26 to 28 days but did not vary over time (p = 0.54). The percentage undergoing tracheostomy significantly decreased from 1.05% in 2003 to 0.27% in 2012 (p = 0.0055), and the percentage undergoing tracheoscopy and laryngoscopy with biopsy significantly decreased from 7.29% in 2003 to 4.20% in 2012 (p = 0.011) among those with IH of unspecified or other sites. The percentage undergoing skin lesion excision also significantly decreased from 1.87% in 2003 to 1.03%, in 2012 (p = 0.0038) among those with IH of skin and subcutaneous tissue. These findings suggest a potential impact of propranolol. After adjusting for inflation, the total hospital charges increased from a mean of $17,838 in 2003 to an adjusted mean of $41,306 in 2012 (p < 0.0001). CONCLUSIONS: Total admissions and hospital charges in children with IH has increased from 2003 to 2012. The percentage of patients undergoing tracheostomy, tracheoscopy and laryngoscopy with biopsy, and skin lesion excision significantly decreased in 2012 compared to 2003, suggesting a potential impact of propranolol. Further studies are needed to examine these changes more closely.
[Mh] Termos MeSH primário: Biópsia/tendências
Endoscopia/tendências
Hemangioma/cirurgia
Traqueostomia/tendências
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Bases de Dados Factuais
Feminino
Hemangioma/tratamento farmacológico
Preços Hospitalares
Hospitalização/estatística & dados numéricos
Seres Humanos
Lactente
Classificação Internacional de Doenças
Tempo de Internação
Masculino
Propranolol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171231
[St] Status:MEDLINE


  2 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454738
[Au] Autor:Miksys S; Wadji FB; Tolledo EC; Remington G; Nobrega JN; Tyndale RF
[Ad] Endereço:Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, Canada; Department of Pharmacology and Toxicology, University of Toronto, Canada. Electronic address: s.miksys@utoronto.ca.
[Ti] Título:Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms.
[So] Source:Prog Neuropsychopharmacol Biol Psychiatry;78:140-148, 2017 Aug 01.
[Is] ISSN:1878-4216
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Risk for side-effects after acute (e.g. parkinsonism) or chronic (e.g. tardive dyskinesia) treatment with antipsychotics, including haloperidol, varies substantially among people. CYP2D can metabolize many antipsychotics and variable brain CYP2D metabolism can influence local drug and metabolite levels sufficiently to alter behavioral responses. Here we investigated a role for brain CYP2D in acutely and chronically administered haloperidol levels and side-effects in a rat model. Rat brain, but not liver, CYP2D activity was irreversibly inhibited with intracerebral propranolol and/or induced by seven days of subcutaneous nicotine pre-treatment. The role of variable brain CYP2D was investigated in rat models of acute (catalepsy) and chronic (vacuous chewing movements, VCMs) haloperidol side-effects. Selective inhibition and induction of brain, but not liver, CYP2D decreased and increased catalepsy after acute haloperidol, respectively. Catalepsy correlated with brain, but not hepatic, CYP2D enzyme activity. Inhibition of brain CYP2D increased VCMs after chronic haloperidol; VCMs correlated with brain, but not hepatic, CYP2D activity, haloperidol levels and lipid peroxidation. Baseline measures, hepatic CYP2D activity and plasma haloperidol levels were unchanged by brain CYP2D manipulations. Variable rat brain CYP2D alters side-effects from acute and chronic haloperidol in opposite directions; catalepsy appears to be enhanced by a brain CYP2D-derived metabolite while the parent haloperidol likely causes VCMs. These data provide novel mechanistic evidence for brain CYP2D altering side-effects of haloperidol and other antipsychotics metabolized by CYP2D, suggesting that variation in human brain CYP2D may be a risk factor for antipsychotic side-effects.
[Mh] Termos MeSH primário: Encéfalo/efeitos dos fármacos
Encéfalo/enzimologia
Família 2 do Citocromo P450/metabolismo
Haloperidol/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Encéfalo/metabolismo
Catalepsia/induzido quimicamente
Haloperidol/sangue
Fígado/enzimologia
Masculino
Microinjeções
Nicotina/administração & dosagem
Nicotina/farmacologia
Propranolol/administração & dosagem
Propranolol/farmacologia
Ratos
Discinesia Tardia/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6M3C89ZY6R (Nicotine); 9Y8NXQ24VQ (Propranolol); EC 1.14.14.1 (Cytochrome P450 Family 2); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  3 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352277
[Au] Autor:Villain H; Benkahoul A; Birmes P; Ferry B; Roullet P
[Ad] Endereço:Centre de Recherches sur la Cognition Animale, Centre de Biologie Intégrative, Université de Toulouse, CNRS, UPS, Toulouse, France.
[Ti] Título:Influence of early stress on memory reconsolidation: Implications for post-traumatic stress disorder treatment.
[So] Source:PLoS One;13(1):e0191563, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Post-traumatic stress disorder (PTSD) is a common consequence of exposure to a life-threatening event. Currently, pharmacological treatments are limited by high rates of relapse, and novel treatment approaches are needed. We have recently demonstrated that propranolol, a ß-adrenergic antagonist, inhibited aversive memory reconsolidation in animals. Following this, in an open-label study 70% of patients with PTSD treated with propranolol during reactivation of traumatic memory exhibited full remission. However, the reason why 30% of these patients did not respond positively to propranolol treatment is still unclear. One of the major candidates as factor of treatment resistance is the patient's early-life traumatic history. To test the role of this factor, mice with pre- or postnatal stress are being tested in fear conditioning and in a new behavioral task, the "city-like", specifically designed as a mouse model of PTSD. After reactivation of the traumatic event, mice received propranolol injection to block the noradrenergic system during memory reconsolidation. Results show that, in the "city-like" test, control mice strongly avoided the shock compartment but also the compartments containing cues associated with the electric shocks. Injection of propranolol after reactivation greatly reduced the memory of the traumatic event, but this effect was not present when mice had received pre- or postnatal stress. Moreover, propranolol produced only a very weak effect in the fear conditioning test, and never changed the corticosterone level whatever the behavioral experiment. Taken together our results suggest that our new behavioural paradigm is well adapted to PTSD study in mice, and that early stress exposure may have an impact on propranolol PTSD treatment outcome. These data are critical to understanding the effect of propranolol treatment, in order to improve the therapeutic protocol currently used in humans.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/farmacologia
Consolidação da Memória/efeitos dos fármacos
Consolidação da Memória/fisiologia
Propranolol/farmacologia
Transtornos de Estresse Pós-Traumáticos/tratamento farmacológico
Transtornos de Estresse Pós-Traumáticos/psicologia
[Mh] Termos MeSH secundário: Animais
Condicionamento Clássico
Corticosterona/sangue
Modelos Animais de Doenças
Medo/psicologia
Feminino
Seres Humanos
Camundongos
Gravidez
Efeitos Tardios da Exposição Pré-Natal/tratamento farmacológico
Efeitos Tardios da Exposição Pré-Natal/psicologia
Transtornos de Estresse Pós-Traumáticos/sangue
Estresse Fisiológico
Estresse Psicológico/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 9Y8NXQ24VQ (Propranolol); W980KJ009P (Corticosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191563


  4 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468167
[Au] Autor:Kado M; Shimizu A; Matsumura T; Mochizuki M; Mizuno H; Hayashi A
[Ad] Endereço:*Department of Plastic and Reconstructive Surgery, Juntendo University School of Medicine, Tokyo †Department of Plastic and Reconstructive Surgery, Juntendo University Urayasu Hospital, Chiba ‡Department of Plastic and Reconstructive Surgery, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
[Ti] Título:Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants.
[So] Source:J Craniofac Surg;28(3):789-793, 2017 May.
[Is] ISSN:1536-3732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Infantile hemangioma (IH) is a benign neoplasm that causes scarring and cosmetic problems after spontaneous regression. Therefore, aggressive treatments such as laser irradiation and corticosteroid have been used; however, recently, the effect of propranolol has been widely noticed. In this study, the authors applied propranolol to low-birth-weight infants with IHs and evaluated its effect. METHODS: Four low-birth-weight infants having IH were selected, with birth weights ranging from 582 to 814 g (average 703 g). The administration of propranolol was started within 4 days of hospitalization. The dosage of propranolol was increased from 0.5 to 2.0 mg/kg/day step by step. Vital signs and blood sugar level were checked prior to every administration of the drug. Continuous monitoring of electrocardiography and arterial oxygen saturation were performed during entire hospitalization.The outcomes were assessed by the patient's family and 2 board-certified plastic surgeons based on 5 parameters pertaining to clinical findings, using a scale of 1 to 10. Reduction rate of the hemangioma was calculated at the end of treatment and compared with the size prior to treatment. RESULTS: The authors could administrate propranolol without any severe side effects in all patients. Infantile hemangiomas gradually shrank soon after the authors started the treatment. Reduction ratios were 22.1% to 100% (average 48.72%), and the comprehensive evaluation of treatment was 7.5 to 10 (average 8.55) on a 10-point scale. CONCLUSIONS: With careful monitoring of their vital signs, propranolol could be a good treatment option even for IH in low-birth-weight infants whose birth weights were less than 1000 g.
[Mh] Termos MeSH primário: Hemangioma/tratamento farmacológico
Recém-Nascido de Baixo Peso
Propranolol/uso terapêutico
Neoplasias Cutâneas/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/uso terapêutico
Feminino
Hemangioma/diagnóstico
Seres Humanos
Recém-Nascido
Imagem por Ressonância Magnética
Masculino
Neoplasias Cutâneas/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1097/SCS.0000000000003542


  5 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181470
[Au] Autor:Mangiapia G; Gvaramia M; Kuhrts L; Teixeira J; Koutsioubas A; Soltwedel O; Frielinghaus H
[Ad] Endereço:Forschungszentrum Jülich GmbH, Jülich Centre for Neutron Science Außenstelle am Heinz Maier-Leibnitz Zentrum, Lichtenbergstraße 1, D-85747 Garching, Germany. mangiapia.gaetano@alice.it.
[Ti] Título:Effect of benzocaine and propranolol on phospholipid-based bilayers.
[So] Source:Phys Chem Chem Phys;19(47):32057-32071, 2017 Dec 06.
[Is] ISSN:1463-9084
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cell membranes play a fundamental role in protecting the cell from its surroundings, in addition to hosting many proteins with fundamental biological tasks. A study of drug/lipid interactions is a necessary and important step in fully clarifying the role and action mechanism of active ingredients, and shedding light on possible complications caused by drug overdosage. In this paper, the influence of benzocaine and propranolol drugs on the structure of l-α-phosphatidylcholine-based membranes has been investigated by means of neutron reflectivity, grazing incidence small angle neutron scattering, and small/ultra-small angle neutron scattering. Investigations allowed discovering a stiffening of the membranes and the formation of stalks, caused by the presence of benzocaine. On the other hand, disordered bilayers (lamellar powders) and highly curved structures were found in the presence of propranolol. The results obtained may be rationalized in terms of the molecular structures of drugs and may serve as a starting point for explaining the toxic behavior in long-term and overdosage scenarios.
[Mh] Termos MeSH primário: Benzocaína/farmacologia
Membrana Celular/efeitos dos fármacos
Bicamadas Lipídicas/química
Propranolol/farmacologia
[Mh] Termos MeSH secundário: Anestésicos Locais/farmacologia
Overdose de Drogas/fisiopatologia
Difração de Nêutrons
Fosfolipídeos/química
Espalhamento a Baixo Ângulo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (Lipid Bilayers); 0 (Phospholipids); 9Y8NXQ24VQ (Propranolol); U3RSY48JW5 (Benzocaine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1039/c7cp06077g


  6 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29224766
[Au] Autor:Bangiyev JN; Gurgel R; Vanderhooft SL; Grimmer JF
[Ad] Endereço:University of Utah, Division of Otolaryngology, United States. Electronic address: jbangiyev@gmail.com.
[Ti] Título:Reversible profound sensorineural hearing loss due to propranolol sensitive hemangioma in an infant with PHACE syndrome.
[So] Source:Int J Pediatr Otorhinolaryngol;103:55-57, 2017 Dec.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:PHACE syndrome is the association of large or segmental infantile hemangiomas of the face or scalp with abnormalities within the posterior fossa, arteries, cardiovascular system, and eyes. We present a case of reversible profound sensorineural hearing loss due to a cerebellopontine angle infantile hemangioma that was successfully treated with propranolol.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/uso terapêutico
Coartação Aórtica/complicações
Anormalidades do Olho/complicações
Perda Auditiva Neurossensorial/etiologia
Hemangioma/complicações
Síndromes Neurocutâneas/complicações
Propranolol/uso terapêutico
[Mh] Termos MeSH secundário: Hemangioma/tratamento farmacológico
Seres Humanos
Lactente
Imagem por Ressonância Magnética
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  7 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29061857
[Au] Autor:Maglie R; Caproni M
[Ad] Endereço:Department of Medical and Surgical Critical Care, Section of Dermatology, University of Florence, Florence, Italy maglieroberto78@gmail.com.
[Ti] Título:A case of blood sweating: hematohidrosis syndrome.
[So] Source:CMAJ;189(42):E1314, 2017 10 23.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Hemorragia/diagnóstico
Hemorragia/fisiopatologia
Sudorese
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Face
Feminino
Hemorragia/tratamento farmacológico
Seres Humanos
Propranolol/uso terapêutico
Doenças Raras
Pele/patologia
Síndrome
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.161298


  8 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28977119
[Au] Autor:Chen YZ; Bai N; Bi JH; Liu XW; Xu GQ; Zhang LF; Li XQ; Huo R
[Ad] Endereço:Department of Aesthetic, Plastic, and Burn Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
[Ti] Título:Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms.
[So] Source:Braz J Med Biol Res;50(12):e6138, 2017 Oct 02.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to investigate the mechanism of propranolol on the regression of hemangiomas. Propranolol-treated hemangioma tissues were collected and the expression of hypoxia inducible factor-1α (HIF-1α) was examined. We also established HIF-1α overexpression and knockdown hemangioma cells, and determined the effects of HIF-1α on the hemangioma cells proliferation, apoptosis, migration and tube formation. Significantly increased HIF-1α level was found in the hemangioma tissues compared to that in normal vascular tissues, whereas propranolol treatment decreased the HIF-1α level in hemangioma tissues in a time- and dose-dependent manner. Moreover, propranolol treatment significantly decreased cell proliferation, migration and tube formation as well as promoted cell apoptosis in HIF-1α overexpression and knockdown hemangioma cells. Propranolol suppressed the cells proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms. HIF-1α could serve as a novel target in the treatment of hemangiomas.
[Mh] Termos MeSH primário: Movimento Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Hemangioma/tratamento farmacológico
Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo
Propranolol/uso terapêutico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Apoptose/efeitos dos fármacos
Hemangioma/metabolismo
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoxia-Inducible Factor 1, alpha Subunit); 0 (Vasodilator Agents); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE


  9 / 31575 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28848082
[Au] Autor:Liu Y; Yu X; Zhuang J
[Ad] Endereço:Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
[Ti] Título:Epinephrine Stimulates Cell Proliferation and Induces Chemoresistance in Myeloma Cells through the ß-Adrenoreceptor in vitro.
[So] Source:Acta Haematol;138(2):103-110, 2017.
[Is] ISSN:1421-9662
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To explore the effect of the ß-adrenoreceptor signaling pathway on myeloma cells. METHODS: The myeloma U266 cell line was treated with epinephrine and propranolol. Cell proliferation was analyzed by MTS assay. Apoptosis was detected by flow cytometry. The ß-receptor subtype and the key enzyme of epinephrine were identified by reverse transcription polymerase chain reaction (RT-PCR). RESULTS: Epinephrine (5-50 µM) promoted U266 cell growth in a dose-dependent manner and neutralized the inhibition effect of bortezomib (25 and 50 ng/mL) in vitro. Cell proliferation was inhibited by a ß-receptor antagonist, propranolol, at a concentration of 50-200 µM. The proportions of early and late apoptotic cells were enhanced after treatment with propranolol. The expression of caspase 3/7, 8, and 9 was elevated in propranolol-treated myeloma cells. Both ß1- and ß2-adrenoceptor mRNAs were expressed in the U266 cell line. Key enzymes dopamine hydroxylase and tyrosinehydroxylase were identified in myeloma cells. CONCLUSIONS: Our results reveal that epinephrine stimulates myeloma cell growth in vitro while the ß-blocker propranolol has an antiproliferative effect, indicating that stress hormones may trigger the progression of myeloma.
[Mh] Termos MeSH primário: Proliferação Celular/efeitos dos fármacos
Epinefrina/farmacologia
Receptores Adrenérgicos beta/metabolismo
Vasoconstritores/farmacologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/farmacologia
Apoptose/efeitos dos fármacos
Caspase 3/metabolismo
Linhagem Celular Tumoral
Dopamina/farmacologia
Resistência a Medicamentos Antineoplásicos
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Mieloma Múltiplo/metabolismo
Mieloma Múltiplo/patologia
Propranolol/farmacologia
RNA Mensageiro/metabolismo
Receptores Adrenérgicos beta/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (RNA, Messenger); 0 (Receptors, Adrenergic, beta); 0 (Vasoconstrictor Agents); 9Y8NXQ24VQ (Propranolol); EC 3.4.22.- (Caspase 3); VTD58H1Z2X (Dopamine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1159/000478517


  10 / 31575 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28833230
[Au] Autor:Schwartz T; Faria J; Pawar S; Siegel D; Chun RH
[Ad] Endereço:Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A.
[Ti] Título:Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review.
[So] Source:Laryngoscope;127(11):2665-2672, 2017 Nov.
[Is] ISSN:1531-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Propranolol has recently become the treatment of choice for management of subglottic and airway hemangiomas. This literature review aimed to determine the success rate of propranolol for managing these lesions as well as the rate of rebound growth following propranolol treatment cessation. STUDY DESIGN: Literature search involving MEDLINE and Scopus to identify English-language articles. METHODS: Studies were identified using hemangioma, subglottic or airway, and propranolol for search terms. Studies were eligible for inclusion if they reported the treatment used, individual deidentified patient data, and contained patients without medical or surgical treatment prior to propranolol therapy RESULTS: Initial review included 107 abstracts. Twenty-four articles including case reports and case series met inclusion criteria and were included in the qualitative analysis. Forty-nine patients were included. Twenty-eight (57%) were treated with propranolol alone, and 20 (41%) were treated with a combination of propranolol and a corticosteroid. Thirty-seven (76%) of patients were treated with a dose of 2 mg/kg/d of propranolol. The initial treatment was successful in 43 (88%) of patients. Rebound growth occurred in four (9%) patients. Overall, six (12%) patients underwent surgical resection. CONCLUSIONS: Propranolol is efficacious for treating subglottic hemangiomas. Rebound growth does occur in a small subset of patients during the propranolol wean. Close observation for children during weaning of propranolol therapy for subglottic hemangioma is essential. Adjunctive management strategies need to be used in patients with rebound growth. Laryngoscope, 127:2665-2672, 2017.
[Mh] Termos MeSH primário: Hemangioma/tratamento farmacológico
Propranolol/uso terapêutico
Doenças da Traqueia/tratamento farmacológico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Vasodilator Agents); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1002/lary.26818



página 1 de 3158 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde